Global Chondrosarcoma Epidemiology Market Forecast 2021-2030 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Chondrosarcoma – Epidemiology forecast – 2030” report has been added to ResearchAndMarkets.com’s offering.

This ‘Chondrosarcoma – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical, and forecasted Chondrosarcoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Epidemiology Perspective:

This section encompassing Chondrosarcoma epidemiology provides insights about historical and current patient pool and forecasted trends for every seven major countries. The Chondrosarcoma epidemiology data are studied through all possible divisions to give a better understanding of the Disease scenario in 7MM.

This segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports, and views of key opinion leaders.

Detailed Epidemiology Segmentation:

The Chondrosarcoma epidemiology covered in the report provides historical as well as forecasted Chondrosarcoma epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

• The Chondrosarcoma report covers a detailed overview explaining its etiology, pathophysiology classification, diagnosis and treatment patterns
• The Chondrosarcoma report and model provide an overview of the global trends of Chondrosarcoma in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
• The report provides insight into the historical and forecasted patient pool of Chondrosarcoma in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of Chondrosarcoma.
• The report provides the segmentation of the Chondrosarcoma epidemiology

Key Questions Answered:

• What will be the growth opportunities in the 7MM concerning the patient population pertaining to Chondrosarcoma?
• What are the key findings pertaining to the Chondrosarcoma epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2017-2030)?
• What would be the total number of patients of Chondrosarcoma across the 7MM during the forecast period (2017-2030)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
• What is the disease risk, burden, and unmet needs of Chondrosarcoma?
• What are the currently available treatments of Chondrosarcoma?

Key Topics Covered:

1 Key Insights

2 Executive Summary of Chondrosarcoma

3 SWOT Analysis for Chondrosarcoma

4 Chondrosarcoma Market Overview at a Glance

4.1 Market Share (%) Distribution of Chondrosarcoma In 2017

4.2 Market Share (%) Distribution of Chondrosarcoma In 2030

5 Disease Background and Overview

5.1 Introduction

5.2 Histological grading

5.3 Classification and characteristics of Chondrosarcoma

5.3.1 Conventional chondrosarcoma

5.3.2 Non-conventional chondrosarcoma

5.4 Signaling pathways involved in chondrosarcoma development

5.5 Biomarkers

5.6 Diagnosis

6 Epidemiology and Patient Population

6.1 Key Findings

6.2 7MM Total Incident Patient Population of Chondrosarcoma

6.3 Assumptions and Rationale

6.4 The United States

6.4.1 Incident Population of Chondrosarcoma in the United States

6.4.2 Type-specific cases of Chondrosarcoma in the United States

6.4.3 Type-specific cases of Primary Chondrosarcoma in the United States

6.4.4 Grade-specific cases of Chondrosarcoma in the United States

6.5 EU5 Countries

6.5.1 Germany

6.5.2 France

6.5.3 Italy

6.5.4 Spain

6.5.5 The United Kingdom

6.6 Japan

7 Treatment and Management

7.1 Treatment Guidelines

7.1.1 NCCN Guidelines

7.1.2 ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

8 Case Study

8.1 Intraspinal Mesenchymal Chondrosarcoma: Report of a Pediatric Case and Literature Review

9 Patient Journey

10 Unmet Needs

11 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/opv2lr

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900